Precision BioSciences offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific t...

Read More

DTIL Performance At-A-Glance

RISK EFFICIENCY

-0.83

Precision BioSciences Inc's risk efficiency is -0.83, which is poor. By comparison, the S&P500 is -0.43.

Remained steady  over the past 4 weeks.

DSCORE

9.84%

Precision BioSciences Inc's dScore is 9.84% , which is more volatile than the S&P500 (2.74%).

GROWTH

-72.13%

Precision BioSciences Inc has shrunk by -72.13% over the past year.  By comparison, the S&P500 has lost -10.23%.